MedBright AI Strengthens the Development of MedMatrix As Artificial Intelligence rapidly improves, MedBright AI (Trading as MBAI.c or MBAIF for US investors), a firm dedicated to harnessing the potential of AI in healthcare, is actively investing in AI-centric enterprises for increased patient and doctor welfare.
Their flagship product, MedMatrix, utilizes AI to anticipate patient needs and optimize resource allocation in clinics, with the goal of increasing revenue, improving patient satisfaction, and mitigating physician burnout.
The innovative matching feature is anticipated to raise clinic revenues by 10% without raising costs for the clinics or hospitals, utilizing diverse data sources for accurate predictions.
Last week, MBAI announced the successful completion of its investment in the Limmi Healthcare AI Platform, a move expected to play a crucial role in advancing MedMatrix.
As part of the agreement, MBAI issued 350 common shares of its subsidiary, MB Acquisition Co., to Limmi in exchange for the rights to Limmi's Artificial Intelligence FDA & HIPAA Platform.
These shares can be exchanged for MBAI Class A Shares under specified conditions tied to fundraising and gross profits.
MBAI has taken measures to safeguard the interests of existing shareholders, ensuring that the shares issued under the agreement will likely not become freely tradable for over 2 years.
Additionally, MBAI obtained an option to purchase the Limmi AI Platform by October 2025.
These transactions align seamlessly with MBAI's investment strategy focusing on healthcare AI technologies, in line with its overarching investment policy.
Full Press Release: https://financialpost.com/globe-newswire/medbright-ai-announces-closing-of-investment-in-limmi-healthcare-ai-platform
Posted on behalf of Medbright AI Investments Inc.